CAJ | 학술논문

目的检测NY-ESO-1蛋白在喉鳞癌中的表达情况,探讨其作为喉癌免疫治疗靶标的实验依据及其与喉癌生物学行为的关系.方法免疫组织化学PV-9000两步法检测69例喉鳞癌患者原发灶及其常规病理报告为阳性的121个颈淋巴结中NY-ESO-1的表达,同时采用Western blotting方法检测其在喉鳞癌标本的癌中心区、癌周0.5、1.0 cm及9例全喉切除术患者的喉正常黏膜组织(对照)中的表达.结果 69例喉鳞癌组织中,NY-ESO-1蛋白表达阳性率为43.48%(30/69),在癌中心区、癌周0.5、1.0cm中的表达逐渐下降(P＜0.05),NY-ESO-1在对照组喉正常黏膜组织中无表达.NY-ESO-1蛋白在不同T分级、病理分级和不同颈淋巴结转移喉癌中的表达率差异无统计学意义(P＞0.05),颈转移淋巴结中NY-ESO-1的表达下调.结论 NY-ESO-1在喉鳞癌患者中特异性高表达,可能以某种方式参与了喉癌的发生、发展,是否能将其作为喉癌免疫治疗靶标有待深入研究.
목적 검측NY-ESO-1단백재후린암중적표체정황,탐토기작위후암면역치료파표적실험의거급기여후암생물학행위적관계.방법 면역조직화학PV-9000량보법검측69례후린암환자원발조급기상규병리보고위양성적121개경림파결중NY-ESO-1적표체,동시채용Western blotting방법검측기재후린암표본적암중심구、암주0.5、1.0 cm급9례전후절제술환자적후정상점막조직(대조)중적표체.결과 69례후린암조직중,NY-ESO-1단백표체양성솔위43.48%(30/69),재암중심구、암주0.5、1.0cm중적표체축점하강(P＜0.05),NY-ESO-1재대조조후정상점막조직중무표체.NY-ESO-1단백재불동T분급、병리분급화불동경림파결전이후암중적표체솔차이무통계학의의(P＞0.05),경전이림파결중NY-ESO-1적표체하조.결론 NY-ESO-1재후린암환자중특이성고표체,가능이모충방식삼여료후암적발생、발전,시부능장기작위후암면역치료파표유대심입연구.
Objective To detect the expression of Cancer-Testis antigen NY-ESO-1 in human laryngeal squamous carcinoma (LSC) and to explore its significance in immunotherapeutic application. Methods The expressions of NY-ESO-1 protein in the LSC and in the pathologically positive lymph nodes were detected by PV-9000 Immunohistochemistry. Western blotting was also employed to measure the expressions of NY-ESO-1 in the tumor core region(TC), the tissues at the sites of 0.5cm, 1.0cm away from LSC periphery and the distant normal larynx tissues. Results NY-ESO-1 protein expression was positive in 30 out of 69 (43.48 %) cases of LSC. The expression level of NY-ESO-1 protein were found to significantly decrease by tums in TC and corresponding adjacent tissues (P ＜0.01). None of the nine normal larynx tissues expressed NY-ESO-1 protein.It did not display an obvious correlation between the expression of NY-ESO-1 with T staging, pathological grading and lymph node metastasis (P ＞0.05). Its positive expression was found in pathologically positive cervical lymph nodes, which were significantly lower than that in the primary site (P ＜0.05). Conclusion NY-ESO-1 protein express at high level in human laryngeal squamous carcinoma, and they may play a role in genesis and development of tumors, which suggests that NY-ESO-1 gene might be used as target antigens for immunotherapy of LSC and the further research is necessary.